Anthony DiGiandomenico
Director/Board Member bei ENDRA LIFE SCIENCES INC.
Vermögen: 13 Mio $ am 31.03.2024
Profil
Anthony DiGiandomenico is the founder of Public Ventures LLC, which was founded in 1997.
He is currently a Director at Pier Acquisition I, Inc., Pier Acquisition II, Inc., ENDRA Life Sciences, Inc., National Association of Securities Dealers, Inc., MDB Capital Holdings LLC, and Invizyne Technologies, Inc. He has also held former positions as President & Chief Executive Officer at Digian Co., Director at Orion Acquisition Corp.
II, Director at Charlies Holdings, Inc. from 2004 to 2012, Director at Cue Biopharma, Inc. from 2015 to 2019, and Independent Director at Provention Bio, Inc. from 2017 to 2020.
Mr. DiGiandomenico has an undergraduate degree from The University of Colorado and an MBA from Haas School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MDB CAPITAL HOLDINGS LLC
24,90% | 29.03.2024 | 1 245 000 ( 24,90% ) | 13 Mio $ | 31.03.2024 |
| 29.03.2024 | 26 645 ( 0,62% ) | 273 111 $ | 31.03.2024 | |
ENDRA LIFE SCIENCES INC.
0,93% | 24.03.2024 | 102 434 ( 0,93% ) | 59 412 $ | 31.03.2024 |
Aktive Positionen von Anthony DiGiandomenico
| Unternehmen | Position | Beginn |
|---|---|---|
| ENDRA LIFE SCIENCES INC. | Director/Board Member | 01.07.2013 |
| MDB CAPITAL HOLDINGS, LLC | Director/Board Member | 10.08.2021 |
Pier Acquisition I, Inc.
 Pier Acquisition I, Inc. Financial ConglomeratesFinance Pier Acquisition I, Inc. operates as a blank check company. The company was founded on August 14, 2008 and is headquartered in Calabasas, CA. | Director/Board Member | 16.11.2009 |
Pier Acquisition II, Inc.
 Pier Acquisition II, Inc. Financial ConglomeratesFinance Pier Acquisition II, Inc. was incorporated in the State of Delaware on August 14, 2008. Since inception, the Company has been engaged in organizational efforts and obtaining initial financing. The Company was formed as a vehicle to pursue a business combination and has made no efforts to identify a possible business combination. The Company is considered to be a 'blank check' company. The U.S. Securities and Exchange Commission (the 'SEC') defines as a development stage company. | Director/Board Member | 16.11.2009 |
National Association of Securities Dealers, Inc.
 National Association of Securities Dealers, Inc. Investment Banks/BrokersFinance National Association of Securities Dealers, Inc. provides financial regulatory services. The non-profit company is based in Washington and has subsidiaries in the United States. The American company was founded by Richard B. Jennings, Vince Means. | Corporate Officer/Principal | 25.07.2011 |
Invizyne Technologies, Inc.
 Invizyne Technologies, Inc. Chemicals: SpecialtyProcess Industries Invizyne Technologies, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV. | Director/Board Member | 01.04.2019 |
Ehemalige bekannte Positionen von Anthony DiGiandomenico
| Unternehmen | Position | Ende |
|---|---|---|
| PROVENTION BIO, INC. | Director/Board Member | 19.05.2020 |
| CUE BIOPHARMA, INC. | Director/Board Member | 03.10.2019 |
| CHARLIE'S HOLDINGS, INC. | Director/Board Member | 15.10.2012 |
| ░░░░░ ░░░░░░░░░░░ ░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░ | - |
Ausbildung von Anthony DiGiandomenico
| The University of Colorado | Undergraduate Degree |
| Haas School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CHARLIE'S HOLDINGS, INC. | Producer Manufacturing |
| CUE BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 10 |
|---|---|
| Orion Acquisition Corp. II | Finance |
Public Ventures LLC
 Public Ventures LLC Investment Banks/BrokersFinance Public Ventures LLC is a registered broker-dealer headquartered in Dallas, Texas. The firm was founded by Christopher Marlett and Anthony DiGiandomenico in 1997. They are a wholly-owned subsidiary of MDB Capital Holdings LLC. Public Ventures offers Go-to-Market Strategy, Market Assessments, Revenue Generation and Product Strategy for technology companies that targets the Public Sector. | Finance |
Pier Acquisition I, Inc.
Pier Acquisition I, Inc. Financial ConglomeratesFinance Pier Acquisition I, Inc. operates as a blank check company. The company was founded on August 14, 2008 and is headquartered in Calabasas, CA. | Finance |
Pier Acquisition II, Inc.
Pier Acquisition II, Inc. Financial ConglomeratesFinance Pier Acquisition II, Inc. was incorporated in the State of Delaware on August 14, 2008. Since inception, the Company has been engaged in organizational efforts and obtaining initial financing. The Company was formed as a vehicle to pursue a business combination and has made no efforts to identify a possible business combination. The Company is considered to be a 'blank check' company. The U.S. Securities and Exchange Commission (the 'SEC') defines as a development stage company. | Finance |
| ENDRA Life Sciences, Inc. | |
National Association of Securities Dealers, Inc.
National Association of Securities Dealers, Inc. Investment Banks/BrokersFinance National Association of Securities Dealers, Inc. provides financial regulatory services. The non-profit company is based in Washington and has subsidiaries in the United States. The American company was founded by Richard B. Jennings, Vince Means. | Finance |
| Digian Co. | |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
| MDB Capital Holdings LLC | |
Invizyne Technologies, Inc.
Invizyne Technologies, Inc. Chemicals: SpecialtyProcess Industries Invizyne Technologies, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV. | Process Industries |
